Pfizer Discontinues Development of Two Phase 3 Compounds

Pfizer IncPfizer Inc has announced that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the investigational compounds esreboxetine for fibromyalgia and PD 332,334 for generalized anxiety disorder (GAD).

The decision to terminate these programs will enable the Business Unit to allocate additional resources to higher-potential development programs as part of its continuing effort to deliver greater value to patients and Pfizer shareholders.

After reviewing the results of the first Phase 3 study for PD 332,334 for the treatment of GAD and the existing data for esreboxetine for the treatment of fibromyalgia, along with current market dynamics, it was considered unlikely that either compound would provide meaningful benefit to patients beyond the current standard of care. Neither compound was terminated due to safety reasons.

"While confident in the safety of these compounds, we don't believe that they provide significant benefit over other therapies," said Pedro Lichtinger, President and General Manager, Pfizer's Primary Care Business Unit.

Mr. Lichtinger continued, "In Primary Care, we continually review our portfolio to ensure we are developing medicines in areas of unmet need and have found significant potential opportunities to bring more value to patients and our company. For example, we are advancing the investigational compound tanezumab into areas of pain management beyond osteoarthritis and see potential opportunities for other investigational compounds in other areas of significant patient need, including Alzheimer's disease and thrombosis. Our goal is to use our resources efficiently and effectively to continue to deliver medical innovations to the global health community."

Pfizer will continue to pursue an indication for Lyrica (pregabalin) CV in the treatment of GAD, a chronic disorder characterized by persistent anxiety, exaggerated worry and tension that results in impairment of daily function.

Pfizer is a pioneer in the study of treatments for fibromyalgia, a condition of chronic widespread pain. In June 2007, Lyrica (pregabalin) CV became the first FDA-approved treatment for the management of fibromyalgia, and Pfizer continues to support research and education in this complex pain condition.

Pfizer is notifying all clinical trial investigators involved in studies of both esreboxetine and PD 332,334 to determine the best course of action for their patients. Patients participating in any of these studies should contact their clinical investigational site should they have any questions or concerns.

About Pfizer Inc
Pfizer Inc, founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals. Every day, over 80,000 colleagues in more than 150 countries work to discover, develop, manufacture and deliver quality, safe and effective prescription medicines to patients.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...